NanoRepro (NN6.DE) Stock Price

NanoRepro Price

XETRA·CLOSED
1.90EUR-0.02 (-1.05 %)
Market closed

Revenue has compounded at 23.1% per year over the past 17 years to 4.47 M EUR. NanoRepro's net margin stands at -45.9%, down from 10.0% several years earlier. NanoRepro currently offers a dividend yield of about 7.89%. Analysts set a median price target of 4.59 EUR, implying 141.6% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 38% above its 52-week low.

NanoRepro stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of NanoRepro over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how NanoRepro stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing NanoRepro's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

NanoRepro Stock Price History
DateNanoRepro Price
7/31/20261.90 EUR
7/30/20261.92 EUR
7/29/20261.95 EUR
7/28/20262.09 EUR
7/27/20262.12 EUR
7/24/20262.10 EUR
7/23/20262.12 EUR
7/22/20262.11 EUR
7/21/20262.11 EUR
7/20/20262.21 EUR
7/17/20262.16 EUR
7/16/20262.24 EUR
7/15/20262.29 EUR
7/14/20262.12 EUR
7/13/20262.19 EUR
7/10/20262.15 EUR
7/9/20262.17 EUR
7/8/20262.23 EUR
7/7/20262.24 EUR
7/6/20262.23 EUR
7/3/20262.05 EUR
7/2/20261.91 EUR
7/1/20261.97 EUR
6/30/20261.98 EUR
6/29/20262.00 EUR
6/26/20262.08 EUR
6/25/20262.08 EUR
6/24/20262.09 EUR
6/23/20262.09 EUR
6/22/20261.98 EUR
6/19/20262.02 EUR
6/18/20262.02 EUR
6/17/20262.00 EUR
6/16/20261.87 EUR
6/15/20261.84 EUR
6/12/20261.77 EUR
6/11/20261.78 EUR
6/10/20261.75 EUR
6/9/20261.76 EUR
6/8/20261.77 EUR
6/5/20261.78 EUR
6/4/20261.80 EUR
6/3/20261.80 EUR
6/2/20261.80 EUR
6/1/20261.85 EUR
5/29/20261.83 EUR
5/28/20261.78 EUR
5/27/20261.76 EUR
5/26/20261.67 EUR
5/25/20261.70 EUR
5/22/20261.65 EUR
5/21/20261.65 EUR
5/20/20261.64 EUR
5/19/20261.57 EUR
5/18/20261.57 EUR
5/15/20261.53 EUR
5/14/20261.50 EUR
5/13/20261.49 EUR
5/12/20261.49 EUR
5/11/20261.47 EUR
5/8/20261.50 EUR
5/7/20261.51 EUR
5/6/20261.53 EUR
5/5/20261.52 EUR
5/4/20261.52 EUR
4/30/20261.51 EUR
4/29/20261.53 EUR
4/28/20261.57 EUR
4/27/20261.55 EUR
4/24/20261.54 EUR
4/23/20261.56 EUR
4/22/20261.54 EUR
4/21/20261.52 EUR
4/20/20261.55 EUR
4/17/20261.49 EUR
4/16/20261.47 EUR
4/15/20261.59 EUR
4/14/20261.44 EUR
4/13/20261.41 EUR
4/10/20261.41 EUR
4/9/20261.45 EUR
4/8/20261.46 EUR
4/7/20261.43 EUR
4/2/20261.41 EUR
4/1/20261.39 EUR
3/31/20261.39 EUR
3/30/20261.40 EUR
3/27/20261.38 EUR
3/26/20261.42 EUR
3/25/20261.42 EUR
3/24/20261.40 EUR
3/23/20261.40 EUR
3/20/20261.44 EUR
3/19/20261.47 EUR
3/18/20261.47 EUR
3/17/20261.45 EUR
3/16/20261.46 EUR
3/13/20261.49 EUR
3/12/20261.40 EUR
3/11/20261.54 EUR
3/10/20261.55 EUR
3/9/20261.52 EUR
3/5/20261.55 EUR
3/4/20261.50 EUR
3/3/20261.51 EUR
2/26/20261.54 EUR
2/25/20261.53 EUR
2/24/20261.51 EUR
2/23/20261.50 EUR
2/20/20261.43 EUR
2/19/20261.46 EUR
2/18/20261.46 EUR
2/17/20261.44 EUR
2/16/20261.46 EUR
2/13/20261.52 EUR
2/12/20261.57 EUR
2/11/20261.57 EUR
2/10/20261.46 EUR
2/9/20261.57 EUR
2/6/20261.47 EUR
2/5/20261.48 EUR
2/4/20261.48 EUR
2/3/20261.48 EUR
2/2/20261.56 EUR
1/30/20261.58 EUR
1/29/20261.50 EUR
1/28/20261.57 EUR
1/27/20261.57 EUR
1/26/20261.59 EUR
1/23/20261.53 EUR
1/22/20261.53 EUR
1/21/20261.59 EUR
1/20/20261.59 EUR
1/19/20261.57 EUR
1/16/20261.55 EUR
1/15/20261.46 EUR
1/14/20261.58 EUR
1/13/20261.60 EUR
1/12/20261.60 EUR
1/9/20261.49 EUR
1/8/20261.52 EUR
1/7/20261.50 EUR
1/6/20261.52 EUR
1/5/20261.51 EUR
1/2/20261.50 EUR
12/30/20251.56 EUR
12/29/20251.48 EUR
12/23/20251.56 EUR
12/22/20251.48 EUR
12/19/20251.57 EUR
12/17/20251.51 EUR
12/16/20251.45 EUR
12/12/20251.50 EUR
12/11/20251.50 EUR
12/10/20251.53 EUR
12/9/20251.52 EUR
12/8/20251.54 EUR
12/5/20251.58 EUR
12/4/20251.60 EUR
12/3/20251.51 EUR
12/2/20251.51 EUR
12/1/20251.51 EUR
11/28/20251.52 EUR
11/27/20251.60 EUR
11/26/20251.58 EUR
11/25/20251.53 EUR
11/24/20251.60 EUR
11/21/20251.56 EUR
11/20/20251.54 EUR
11/19/20251.55 EUR
11/18/20251.55 EUR
11/17/20251.53 EUR
11/14/20251.60 EUR
11/13/20251.55 EUR
11/12/20251.59 EUR
11/11/20251.60 EUR
11/10/20251.65 EUR
11/7/20251.63 EUR
11/6/20251.65 EUR
11/5/20251.65 EUR
11/4/20251.67 EUR
11/3/20251.70 EUR
10/31/20251.69 EUR
10/30/20251.79 EUR
10/29/20251.76 EUR
10/28/20251.79 EUR
10/27/20251.76 EUR
10/24/20251.69 EUR
10/23/20251.59 EUR
10/22/20251.52 EUR
10/21/20251.68 EUR
10/20/20251.68 EUR
10/17/20251.62 EUR
10/16/20251.74 EUR
10/15/20251.74 EUR
10/14/20251.75 EUR
10/13/20251.70 EUR
10/10/20251.74 EUR
10/9/20251.72 EUR
10/8/20251.73 EUR
10/7/20251.75 EUR
10/6/20251.71 EUR
10/3/20251.79 EUR
10/2/20251.72 EUR
10/1/20251.73 EUR
9/30/20251.74 EUR
9/29/20251.77 EUR
9/26/20251.77 EUR
9/25/20251.81 EUR
9/24/20251.73 EUR
9/23/20251.75 EUR
9/22/20251.74 EUR
9/19/20251.70 EUR
9/18/20251.71 EUR
9/17/20251.75 EUR
9/16/20251.84 EUR
9/15/20251.88 EUR
9/12/20251.78 EUR
9/11/20251.70 EUR
9/10/20251.72 EUR
9/9/20251.86 EUR
9/8/20251.78 EUR
9/5/20251.86 EUR
9/4/20251.94 EUR
9/3/20251.90 EUR
9/2/20251.86 EUR
9/1/20251.95 EUR
8/29/20251.94 EUR
8/28/20251.94 EUR
8/27/20251.96 EUR
8/26/20252.00 EUR
8/25/20251.89 EUR
8/22/20251.88 EUR
8/21/20251.88 EUR
8/20/20251.70 EUR
8/19/20251.64 EUR
8/18/20251.64 EUR
8/15/20251.60 EUR
8/14/20251.65 EUR
8/13/20251.62 EUR
8/12/20251.65 EUR
8/11/20251.60 EUR
8/8/20251.57 EUR
8/7/20251.56 EUR
8/6/20251.55 EUR
8/5/20251.58 EUR
8/4/20251.61 EUR
Access this data via the Eulerpool API
Get Free API Key

NanoRepro Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
1.22 M EUR
-1.18 M EUR
-1.19 M EUR
Jan 1, 2020
16.93 M EUR
4.65 M EUR
1.70 M EUR
Jan 1, 2021
162.72 M EUR
38.81 M EUR
29.72 M EUR
Jan 1, 2022
38.79 M EUR
-4.53 M EUR
-3.72 M EUR
Jan 1, 2023
3.18 M EUR
-5.34 M EUR
-4.69 M EUR
Jan 1, 2024
4.47 M EUR
-3.62 M EUR
-2.05 M EUR
Jan 1, 2025 (e)
14.88 M EUR
-2.81 M EUR
-2.10 M EUR
Jan 1, 2026 (e)
18.68 M EUR
161,600.00 EUR
0.00 EUR

NanoRepro Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 2, 2026, 1:16 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
201120122013201420152016201720182019202020212022202320242025e2026e
––1.00––1.001.002.001.0016.00162.0038.003.004.0014.0018.00
–––––––100.00-50.001,500.00912.50-76.54-92.1133.33250.0028.57
––200.00––200.00100.0050.00100.0043.7534.5728.9533.3350.0050.0050.00
2.002.002.002.002.002.001.001.001.007.0056.0011.001.002.007.009.00
-1.00–––-1.00-1.00––-1.004.0038.00-4.00-5.00-3.00-2.00–
–––––-100.00––-100.0025.0023.46-10.53-166.67-75.00-14.29–
-1.00–––-1.00–––-1.001.0029.00-3.00-4.00-2.00-2.00–
–––––––––-200.002,800.00-110.3433.33-50.00––
––––––––––0.500.500.15–0.150.15
––––––––––––-70.00–––
1.232.423.123.434.525.897.138.658.659.3312.9012.9013.0013.0013.0013.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales NanoRepro generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue NanoRepro retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare NanoRepro's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares NanoRepro has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against NanoRepro's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

NanoRepro stock margins

The NanoRepro margin analysis displays the gross margin, EBIT margin, as well as the profit margin of NanoRepro. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for NanoRepro.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
109.14 %
-96.84 %
-97.56 %
Jan 1, 2020
45.07 %
27.49 %
10.01 %
Jan 1, 2021
34.77 %
23.85 %
18.27 %
Jan 1, 2022
30.27 %
-11.68 %
-9.59 %
Jan 1, 2023
57.55 %
-167.92 %
-147.48 %
Jan 1, 2024
61.97 %
-80.98 %
-45.86 %
Jan 1, 2025 (e)
61.97 %
-18.87 %
-14.12 %
Jan 1, 2026 (e)
61.97 %
0.87 %
0.00 %

NanoRepro Stock Revenue, EBIT, Earnings per Share

The NanoRepro earnings per share therefore indicates how much revenue NanoRepro has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.14 EUR
-0.14 EUR
-0.14 EUR
Jan 1, 2020
1.81 EUR
0.50 EUR
0.18 EUR
Jan 1, 2021
12.61 EUR
3.01 EUR
2.30 EUR
Jan 1, 2022
3.01 EUR
-0.35 EUR
-0.29 EUR
Jan 1, 2023
0.24 EUR
-0.41 EUR
-0.36 EUR
Jan 1, 2024
0.34 EUR
-0.28 EUR
-0.16 EUR
Jan 1, 2025 (e)
1.14 EUR
-0.22 EUR
-0.16 EUR
Jan 1, 2026 (e)
1.44 EUR
0.01 EUR
0.00 EUR

NanoRepro business model & stock analysis

The Nanorepro AG was founded in 1998 in Marburg an der Lahn and has since developed into a leading company in the development and production of diagnostic rapid tests and self-tests. The company has been listed on the Frankfurt Stock Exchange since 2006 and has its headquarters in the university city of Marburg. Nanorepro's business model focuses on the production and distribution of innovative, reliable, and easy-to-use self-tests for the medical field. The company concentrates on the practical application of the tests - they should be simple, fast, and user-friendly. Nanorepro's core competence lies in the design, production, and distribution of rapid tests and self-tests for the medical field. The company relies on close cooperation with other companies and research institutions to continuously improve the tests and develop new products. Nanorepro focuses on various areas, including the manufacturing of rapid tests and self-tests for the diagnosis of infectious diseases. In addition, the company also offers tests to check pregnancy status or determine ovulation. Nanorepro's range of products also includes self-tests for the early detection of diseases such as diabetes. With its wide range of products, the company is able to address a large customer base and achieve a positive market position. One key product of Nanorepro is the early pregnancy test. This product is easy to handle and allows women to quickly and safely determine if they are pregnant or not. Nanorepro also offers an ovulation test to help women determine the timing of ovulation. Another test offered by the company is the Lyme borreliosis self-test, which allows for the detection of antibodies to Lyme borreliosis. Nanorepro also offers numerous tests for diagnosing infectious diseases. These include tests that can diagnose bacterial or viral infections such as streptococcal infections or hepatitis B and C. The tests are highly accurate and reliable, enabling quick diagnosis and treatment. Another area in which Nanorepro is expanding is the development of self-tests for the early detection of cancer. For this purpose, the company works closely with scientific and research institutions to continuously improve the tests and make them even more precise and reliable. Nanorepro places a strong emphasis on quality control and safety in the production of the tests. The products are CE-certified, ensuring high quality and safety for the user. In addition, the company has been certified according to the standards of the International Quality Management System ISO 13485, guaranteeing a high standard in the production and marketing of medical devices. Overall, Nanorepro AG has established itself as a leading company in the field of rapid tests and self-tests. With its wide range of products and constant willingness to innovate, the company is able to quickly and effectively respond to the requirements of customers and partners. The company's extensive experience in the field of medical diagnostics contributes to Nanorepro being perceived as a reliable partner in medical technology.

NanoRepro SWOT Analysis

Strengths

Nanorepro AG has several strengths that contribute to its success in the market. Firstly, the company specializes in the development and manufacturing of rapid diagnostic tests, which are in high demand across various industries. This expertise allows Nanorepro AG to deliver accurate and reliable products to its customers.

Another strength of Nanorepro AG is its strong research and development capabilities. The company continuously invests in innovation, allowing them to stay at the forefront of technological advancements in the diagnostics industry. This helps Nanorepro AG to maintain a competitive edge and offer cutting-edge solutions to its customers.

Furthermore, Nanorepro AG has established a vast distribution network, enabling it to reach a wide customer base globally. This network allows for efficient product delivery and customer support, enhancing customer satisfaction and loyalty.

Weaknesses

Despite its strengths, Nanorepro AG also faces certain weaknesses that need to be addressed. One of these weaknesses is the company's heavy reliance on a few key clients. This dependency poses a risk to Nanorepro AG's revenue and growth potential, as the loss or reduction of business from these clients could significantly impact the company's financial performance.

Additionally, the company's product portfolio may not be as diverse as some of its competitors. This narrow focus could limit Nanorepro AG's market reach and potentially hinder its ability to cater to a broader customer base.

Opportunities

Nanorepro AG operates in a growing market for rapid diagnostic tests, providing numerous opportunities for expansion. With the increasing demand for quick and accurate diagnostics, the company can capitalize on this trend by introducing new products or enhancing existing ones to target specific market segments.

Additionally, Nanorepro AG can explore potential partnerships or collaborations with other companies in related industries. By leveraging the synergies of such alliances, the company can access new markets, technologies, and expertise, leading to increased growth and market share.

Threats

Nanorepro AG faces several threats that could impact its operations and market position. One significant threat is the intense competition within the diagnostic industry. Competitors with larger resources and established market presence may pose challenges to Nanorepro AG's growth and market share.

Additionally, external factors such as regulatory changes or disruptions in the supply chain could also pose threats to the company's operations. Adapting to evolving regulations and ensuring a robust supply chain management system are crucial for Nanorepro AG to mitigate these risks.

Lastly, economic downturns and market uncertainties can affect customer spending and demand for diagnostic products, potentially impacting Nanorepro AG's revenue and profitability.

NanoRepro Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

NanoRepro historical P/E ratio, EBIT multiple, and P/S ratio

NanoRepro annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

NanoRepro shares outstanding

The number of shares of NanoRepro was 13 M in 2025. This indicates how many shares NanoRepro is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
8.65 M Stocks
Jan 1, 2020
9.33 M Stocks
Jan 1, 2021
12.90 M Stocks
Jan 1, 2022
12.90 M Stocks
Jan 1, 2023
13.00 M Stocks
Jan 1, 2024
13.00 M Stocks
Jan 1, 2025 (e)
13.00 M Stocks
Jan 1, 2026 (e)
13.00 M Stocks

NanoRepro Dividend History

3 years of dividend payments

YearAnnual DividendYoY ChangePayments
20230.15EUR↓ 70.0%1×
20220.50EUR 0.0%1×
20210.50EUR——

NanoRepro dividend history and estimates

In 2025, NanoRepro paid a dividend amounting to 0.15 EUR. Dividend means that NanoRepro distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.50 EUR
0.00 EUR
Jan 1, 2022 (e)
0.00 EUR
0.50 EUR
Jan 1, 2023
0.15 EUR
0.00 EUR
Jan 1, 2025 (e)
0.00 EUR
0.15 EUR
Jan 1, 2026 (e)
0.00 EUR
0.15 EUR

NanoRepro dividend payout ratio

In 2025, NanoRepro had a payout ratio of 0.00%. The payout ratio indicates the percentage of the company's profits that NanoRepro distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2019
0.00 %
Jan 1, 2020
0.00 %
Jan 1, 2021
0.00 %
Jan 1, 2022
-173.01 %
Jan 1, 2023
-41.67 %
Jan 1, 2024
0.00 %
Jan 1, 2025 (e)
0.00 %
Jan 1, 2026 (e)
0.00 %

Current NanoRepro forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
4.59
Last Price
1.90
Currency
EUR
12M Return Potential
141.58 %
LTM Return
0 %

NanoRepro shareholder structure

% Name
7.99708%
TBF Global Asset Management GmbH
TBF Global Asset Management GmbH
1.98519%
Vorstand und Aufsichtsrat des Nanorepro AG
Vorstand und Aufsichtsrat des Nanorepro AG
0.25298%
SALUTARIS Capital Management AG
SALUTARIS Capital Management AG
0.00000%
Discover Capital GmbH
Discover Capital GmbH

NanoRepro Executives and Management Board

OS

Dr. Olaf Stiller

(48)

Chairman of the Supervisory Board · since 2007

LJ

Ms. Lisa Juengst

Chief Executive Officer, Member of the Executive Board · since 2020

EB

Ms. Eva Blank

Deputy Chairwomen of the Supervisory Board · since 2023

SP

Mr. Stefan Pieh

Chief Financial Officer, Member of the Executive Board

AS

Mr. Andre Schulte-Sudhof

Member of the Supervisory Board

NanoRepro Supply Chain

NanoRepro Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#Name1M3M6M1Y2YTrend
1
Amazon.com
0.61
0.55
0.75
0.56
0.31

Frequently asked questions about NanoRepro

The business model of Nanorepro AG, a leading healthcare company, focuses on the development and commercialization of innovative medical diagnostics. Nanorepro specializes in rapid, easy-to-use diagnostics for various medical conditions, including fertility, infectious diseases, allergies, and drug tests. With a strong emphasis on research and development, Nanorepro continuously expands its product portfolio to cater to the evolving healthcare needs of individuals and healthcare professionals worldwide. Through its cutting-edge technologies and strategic partnerships, Nanorepro aims to improve patient outcomes by providing accurate and timely diagnostic solutions.

All fundamentals and in-depth analysis of NanoRepro

Our stock analysis for NanoRepro stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NanoRepro. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

NanoRepro Stock
NanoRepro Revenue→
NanoRepro Stock
NanoRepro Net Income→
NanoRepro Stock
NanoRepro P/E→
NanoRepro Stock
NanoRepro P/S→
NanoRepro Stock
NanoRepro EBIT→
NanoRepro Stock
NanoRepro Dividend→
NanoRepro Stock
NanoRepro Directors Dealings→
NanoRepro Stock
NanoRepro Stocks→
NanoRepro Stock
NanoRepro Market capitalization→
NanoRepro Stock
NanoRepro Debt→
NanoRepro Stock
NanoRepro Liabilities→
NanoRepro Stock
NanoRepro Equity→
NanoRepro Stock
NanoRepro AAQS→
NanoRepro Stock
NanoRepro Employees→
NanoRepro Stock
NanoRepro ROE→
NanoRepro Stock
NanoRepro ROA→
NanoRepro Stock
NanoRepro ROCE→
NanoRepro Stock
NanoRepro News→
NanoRepro Stock
NanoRepro Analyst Price Targets→

Health Stocks

NanosonicsNanologica AB (publ)NanoViricides,NanolloseNarayana HrudayalayaNanogroupNatco PharmaNanoform Finland OyjNateraNanoEnTekNational GraphiteNanobiotixAll Stocks A–Z →